Tumor slice culture system to assess drug response of primary breast cancer.
Tumor slice culture system to assess drug response of primary breast cancer.
复制标题
DOI：
10.1186/s12885-016-2119-2
复制
发表时间：
2016-02-09
期刊：
影响因子：
3.8
通讯作者：
van Gent DC
中科院分区：
文献类型：
--
作者：
Naipal KA;Verkaik NS;Sánchez H;van Deurzen CH;den Bakker MA;Hoeijmakers JH;Kanaar R;Vreeswijk MP;Jager A;van Gent DC
乳腺癌的高发病率激发了新型靶向和个性化治疗的发展。癌症治疗的个性化需要对个别患者的化疗反应进行可靠的预测。有效的选择可以防止不必要的治疗，这主要会导致治疗的不必要的副作用。这种选择可以通过使用强大的和特定的功能分析来表征单个肿瘤，这需要开发强大的离体培养系统和程序来分析对治疗的反应。我们优化了原发乳腺肿瘤样本的培养方法，使组织在体外繁殖。我们结合了几种组织培养策略，包括明确的组织切片技术，培养基优化和使用旋转平台来增加营养交换。我们可以维持组织培养至少7天，而不会失去组织形态，活力或细胞增殖。我们还开发了一些方法来确定单个肿瘤对化疗治疗FAC （5-FU、阿霉素[阿霉素]和环磷酰胺）的细胞毒性反应。使用该工具，我们将肿瘤指定为敏感或耐药，并将临床证明的耐药肿瘤与其他肿瘤区分开来。这种方法确定了允许对个体肿瘤对抗癌药物的反应进行体外测试的条件，因此可能会改善乳腺癌治疗的个性化。本文的在线版本（doi:10.1186/s12885-016-2119-2）包含补充材料，可供授权用户使用。
The high incidence of breast cancer has sparked the development of novel targeted and personalized therapies. Personalization of cancer treatment requires reliable prediction of chemotherapy responses in individual patients. Effective selection can prevent unnecessary treatment that would mainly result in the unwanted side effects of the therapy. This selection can be facilitated by characterization of individual tumors using robust and specific functional assays, which requires development of powerful ex vivo culture systems and procedures to analyze the response to treatment. We optimized culture methods for primary breast tumor samples that allowed propagation of tissue ex vivo. We combined several tissue culture strategies, including defined tissue slicing technology, growth medium optimization and use of a rotating platform to increase nutrient exchange. We could maintain tissue cultures for at least 7 days without losing tissue morphology, viability or cell proliferation. We also developed methods to determine the cytotoxic response of individual tumors to the chemotherapeutic treatment FAC (5-FU, Adriamycin [Doxorubicin] and Cyclophosphamide). Using this tool we designated tumors as sensitive or resistant and distinguished a clinically proven resistant tumor from other tumors. This method defines conditions that allow ex vivo testing of individual tumor responses to anti-cancer drugs and therefore might improve personalization of breast cancer treatment. The online version of this article (doi:10.1186/s12885-016-2119-2) contains supplementary material, which is available to authorized users.